ALMR — Alamar Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $1.42bn
- $1.43bn
- $74.21m
Annual cashflow statement for Alamar Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -47.1 | -29.8 |
| Depreciation | ||
| Non-Cash Items | 0.393 | 5.18 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -11.7 | -32.8 |
| Change in Accounts Receivable | ||
| Change in Inventories | ||
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Cash from Operating Activities | -55.2 | -53.6 |
| Capital Expenditures | -3.39 | -6.38 |
| Purchase of Fixed Assets | ||
| Software Development Costs | ||
| Other Investing Cash Flow Items | -50.5 | 52.6 |
| Sale of Fixed Assets | ||
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | -53.9 | 46.2 |
| Financing Cash Flow Items | 0 | -0.657 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 113 | 10.8 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 4.27 | 3.23 |